Zynex (OTCMKTS:ZYXI) had its price objective increased by B. Riley from $9.00 to $10.75 in a research note published on Friday morning, BenzingaRatingsTable reports. B. Riley currently has a buy rating on the stock. B. Riley also issued estimates for Zynex’s Q3 2019 earnings at $0.05 EPS, Q4 2019 earnings at $0.06 EPS, FY2019 earnings at $0.25 EPS and FY2020 earnings at $0.34 EPS.
Separately, Zacks Investment Research raised Zynex from a sell rating to a hold rating in a report on Thursday, June 27th.
Shares of OTCMKTS ZYXI opened at $8.75 on Friday. The firm has a market capitalization of $291.34 million, a PE ratio of 39.77 and a beta of 1.05. Zynex has a 12-month low of $2.40 and a 12-month high of $11.75. The company has a fifty day moving average of $8.98.
In related news, CEO Thomas Sandgaard sold 50,000 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $8.88, for a total value of $444,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Daniel J. Moorhead sold 25,000 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $7.17, for a total value of $179,250.00. The disclosure for this sale can be found here. Insiders sold 188,750 shares of company stock worth $1,499,223 in the last three months.
Several hedge funds have recently modified their holdings of the business. Strs Ohio purchased a new position in shares of Zynex during the second quarter worth about $37,000. O Shaughnessy Asset Management LLC purchased a new position in shares of Zynex during the first quarter worth about $118,000. WealthTrust Axiom LLC purchased a new position in shares of Zynex during the first quarter worth about $132,000. Finally, Sigma Planning Corp purchased a new position in shares of Zynex during the first quarter worth about $63,000. 0.05% of the stock is currently owned by institutional investors.
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Further Reading: What is a balanced fund?
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.